EMSLIMITED

**Order Wins & Pharma Licensing** **

:** Secured a **₹222 crore** order, strengthening its order book and execution pipeline. **Impact:** **Positive;** improves revenue visibility and supports near-term growth. ** !RVNL:** Secured a **₹161 crore** order for railway infrastructure works. **Impact:** **Positive;** strengthens the order book and supports future revenue growth. **Mankind Pharma:** Entered into an **exclusive in-licensing agreement** for **Insulin Degludec** and the **Insulin Degludec + Insulin Aspart** combination for the Indian market. The products are long-acting and combination insulin therapies used in diabetes management, expanding Mankind's presence in the growing diabetes-care segment. **Impact:** **Positive;** strengthens the company's chronic therapy portfolio and provides an opportunity to capture a larger share of India's diabetes market.